-
Citi On BMY Product Trends For The Week Ending 2/11
Tuesday, February 22, 2011 - 9:53am | 295In its look at Bristol-Myers Squibb (NYSE: BMY) product trends for the week ending 2-11-11, Citi reports the following. “Onglyza: ~$270M Annual Run Rate Implied by 4-Wk Avg TRx's vs. Our 2011E US Sales of $190M,” Citi writes. “Onglyza posted weekly NRx/TRx of 12,469 (+5%)/30,443 (+1%), with DPP-IV...
-
Citi On PFE Product Trends Week Ended 2/11
Tuesday, February 22, 2011 - 9:43am | 299In its look at Pfizer, Inc.'s (NYSE: PFE) product trends for the week ending 2-11-11, Citi reports on the following: “Lipitor NRx/TRx Share Was 20.9% (+2bps)/21.1% (-5bps),” Citi writes. “Lipitor NRx's/TRx's were 395,147 (-2% seq)/1,149,627 (-4%), rolling 4wk/12wk NRx's were down - 9%/-8%; TRxs -5...
-
Citi On ENDP Core Product Pricing & Trends
Tuesday, February 22, 2011 - 9:19am | 327In its look at Endo Pharmaceuticals Holdings Inc.'s (NASDAQ: ENDP) core product pricing and trends for the week ending 2-11-11, Citi reports on the following products: “Lidoderm: ~$970M Annual Run Rate Implied by 4-Wk Avg. TRx's vs. Our 2011E Sales of ~$800M (+2%),” Citi writes. “4Q10 growth was +1...
-
Portfolio Construction Philosophy
Tuesday, February 22, 2011 - 9:15am | 1075Seeking Alpha contributor David Van Knapp asked the following question on my post the other day about efficient portfolio construction in relation to account size; Roger, do you have a template for general asset allocation, one that perhaps serves as a starting point (with variations for individual...
-
Forest Laboratories to Acquire Clinical Data
Tuesday, February 22, 2011 - 9:04am | 171Forest Laboratories, Inc. (NYSE: FRX) and Clinical Data, Inc. (NASDAQ: CLDA) today announced that they have entered into a definitive merger agreement pursuant to which Forest will acquire Clinical Data for $30.00 per share in cash plus contingent consideration of up to $6.00 per share that may be...
-
Merger Arbitrage Mondays – February 21, 2011
Monday, February 21, 2011 - 11:38am | 4843Merger activity decreased last week with five new deals announced and four deals closing. You can find all the deals listed below in our Merger Arbitrage Tool that automatically updates itself during market hours. Deal Statistics: Total Number of Deals Closed in 2011 23 Total Number of Pending...
-
Perrigo Co. Vice-President Sells 4,000 Shares of PRGO
Friday, February 18, 2011 - 5:08pm | 53In a Form 4 filed earlier today, Perrigo Co. (NASDAQ: PRGO) Vice-President, Todd Kingma, reported that he sold 4,000 shares of PRGO on February 16th for an average price of $74.56. The transaction totaled $298,241. Mr. Kingma owns 20,345 direct shares and 300 indirect shares of PRGO. Source: The...
-
ETF Showdown: A Biotech Battle
Friday, February 18, 2011 - 5:05pm | 459The world of biotech. So much profit potential, so much potential for peril at the hands of the FDA and so many takeover targets for big pharma. Indeed this is a sector that is rarely full of dull moments. A prime example of this being Sanofi-Aventis (NYSE: SNY) and its drawn-out tryst with Genzyme...
-
Perrigo Co. Director Sells 287,651 Shares of PRGO
Friday, February 18, 2011 - 4:58pm | 54In a Form 4 filed earlier today, Perrigo Co. (NASDAQ: PRGO) Director, Moshe Arkin, reported that he sold 287,651 shares of PRGO on February 16th-17th for an average price of $75.13. The transaction totaled $21,611,910. Mr. Arkin owns 1,130 direct shares and 6,521,224 indirect shares of PRGO....
-
Stocks on the Move:(MDCO) New High
Friday, February 18, 2011 - 11:22am | 14Stocks on the Move:(MDCO) New High
-
Abbott Increases Quarterly Dividend by 9% to $0.48
Friday, February 18, 2011 - 11:03am | 70The board of directors of Abbott (NYSE: ABT) today increased the company's quarterly common dividend 9 percent to 48 cents per share. This marks the 39th consecutive year that Abbott has increased its dividend payout and the 349th consecutive quarterly dividend to be paid by Abbott since 1924....
-
Duncan-Williams Ups ISPH To Hold
Friday, February 18, 2011 - 7:44am | 40Analysts at Duncan-Williams upgrade Inspire Pharmaceuticals Inc (NASDAQ: ISPH) from “sell” to “hold.” ISPH shares gained 2.61% to close at $4.33 yesterday. More Analyst Ratings here
-
US Stock Market Daily Report (February 17, 2011, Thursday)
Thursday, February 17, 2011 - 4:42pm | 300Stocks were rallying today after news broke of new pharmaceutical mergers and better than expected earnings. Investors were happy to hear before the opening bell that Sanofi-Aventis (NYSE: SNY) agreed to purchase biotech company Genzyme (NASDAQ: GENZ) in a cash deal worth $20.1 billion. Any time...
-
Perrigo Enters Into Exclusive Sales and Distribution Agreement With AgaMatrix
Thursday, February 17, 2011 - 9:18am | 96Perrigo (Nasdaq: PRGO) today announced that it has entered into an exclusive agreement with AgaMatrix, Inc. to sell and distribute blood glucose monitors and test strips in the U.S. store brand channel. As part of the agreement, Perrigo will sell and distribute certain products in the current...
-
Benzinga's Top Pre-Market NASDAQ Gainers (RBCN, OREX, ISPH, BRCD)
Thursday, February 17, 2011 - 9:14am | 141Rubicon Technology Inc (NASDAQ: RBCN) rose 22.64% to $25.89 in the pre-market session. RBCN reported better-than-expected Q4 results. Orexigen Therapeutics Inc (NASDAQ: OREX) added 5.88% to $3.60 in the pre-market session. OREX shares have dropped 47.37% over the past 52 weeks, while the S&P...